-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 VxCjzlt4NHyUsTdFNvjarkjDE86qda5heJLqKrrkmJ2exPCv8q1mh1cVKqCGGwEv
 9drjtEQq0nSKfQ7EU+x+jw==

<SEC-DOCUMENT>0000911420-05-000457.txt : 20051019
<SEC-HEADER>0000911420-05-000457.hdr.sgml : 20051019
<ACCEPTANCE-DATETIME>20051019205730
ACCESSION NUMBER:		0000911420-05-000457
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20051017
FILED AS OF DATE:		20051019
DATE AS OF CHANGE:		20051019

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ENZO BIOCHEM INC
		CENTRAL INDEX KEY:			0000316253
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				132866202
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			0731

	BUSINESS ADDRESS:	
		STREET 1:		60 EXECUTIVE BLVD
		CITY:			FARMINGDALE
		STATE:			NY
		ZIP:			11735
		BUSINESS PHONE:		5167555500

	MAIL ADDRESS:	
		STREET 1:		ENZO BIOCHEM INC
		STREET 2:		60 EXECUTIVE BLVD
		CITY:			FARMINGDALE
		STATE:			NY
		ZIP:			11735

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			RABBANI ELAZAR
		CENTRAL INDEX KEY:			0000903568

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-09974
		FILM NUMBER:		051146108
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>p1128261_ex.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0202</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2005-10-17</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0000316253</issuerCik>
        <issuerName>ENZO BIOCHEM INC</issuerName>
        <issuerTradingSymbol>ENZ</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0000903568</rptOwnerCik>
            <rptOwnerName>RABBANI ELAZAR</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ENZO BIOCHEM, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>527 MADISON AVENUE</rptOwnerStreet2>
            <rptOwnerCity>NEW YORK</rptOwnerCity>
            <rptOwnerState>NY</rptOwnerState>
            <rptOwnerZipCode>10022</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chairman and CEO</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock, par value $.01 per share</value>
            </securityTitle>
            <transactionDate>
                <value>2005-10-17</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>M</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>67005</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>11.0067</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>2194123</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock, par value $.01 per share</value>
            </securityTitle>
            <transactionDate>
                <value>2005-10-17</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>F</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>54670</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>13.49</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>2194123</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">This transaction was a cashless exercise of options to purchase 67,005 shares of Common Stock. The exercise price for the
stock options was paid in the form of 54,670 shares of Common Stock owned by the Reporting Person valued at an aggregate of
$737,500 based on the $13.49 closing price of Enzo Biochem's Common Stock on October 17, 2005, the exercise date.</footnote>
        <footnote id="F2">As of the date hereof, the Reporting Person directly beneficially owns 1,716,782 shares of Common Stock, 3,487 shares of
Common Stock in Enzo Biochem's 401K plan and 468,217 options to purchase Common Stock, par value $.01 per share which are
currently exercisable. The Reporting Person also has an indirect beneficial interest in 3,469 shares in the name of his
children and 2,168 shares in the name of his wife as custodian for his children.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Elazar Rabbani</signatureName>
        <signatureDate>2005-10-19</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----